Ursodeoxycholic Acid in C. Difficile Infection
NCT05526807 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2024-04-09
Summary
The primary objective of the study is to assess tolerability and adherence to treatment with ursodeoxycholic acid
Conditions
- Clostridioides Difficile Infection
Interventions
- DRUG
-
Ursodeoxycholic acid
Oral
Sponsors & Collaborators
-
Nottingham University Hospitals NHS Trust
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-05-08
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
C. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI.
NCT07250724 ·Status: RECRUITING
-
PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA
NCT04259931 ·Status: UNKNOWN
-
C. Difficile and Ursodiol
NCT02748616 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection
NCT02053181 ·Status: COMPLETED ·Phase: PHASE1
-
C.Difficile Observational Study
NCT06277999 ·Status: COMPLETED
-
Fidaxomicin to Prevent Clostridium Difficile Colonization
NCT01552668 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection
NCT01259726 ·Status: COMPLETED ·Phase: PHASE2
-
Clostridioides Difficile Colonisation
NCT05693077 ·Status: RECRUITING ·Phase: PHASE1
-
Host Immune Response to Clostridium Difficile Infection (ICD)
NCT02440438 ·Status: COMPLETED ·Phase: NA
-
Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea
NCT01670149 ·Status: COMPLETED ·Phase: PHASE4
-
CMTS0929 for Clostridioides Difficile Infection
NCT06836427 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
NCT02237859 ·Status: UNKNOWN ·Phase: PHASE4
-
Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection
NCT02148601 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
NCT02951702 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Bismuth Subsalicylate in Clostridium Difficile Colitis
NCT03592082 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
NCT01232595 ·Status: COMPLETED ·Phase: PHASE2
-
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
NCT04940468 ·Status: COMPLETED ·Phase: NA
-
Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin
NCT05201079 ·Status: COMPLETED ·Phase: PHASE3
-
FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI
NCT02255305 ·Status: TERMINATED ·Phase: PHASE2
-
Study of CB-183,315 in Participants With Clostridium Difficile Infection
NCT01085591 ·Status: COMPLETED ·Phase: PHASE2
-
Ultrasound Diagnosis of Antibiotic Associated Diarrhea
NCT00658151 ·Status: UNKNOWN
-
Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes
NCT00446355 ·Status: COMPLETED
-
Pathogenic Mechanisms in C Diff Infection and Colitis
NCT01930032 ·Status: COMPLETED
-
Immune Response to C.Difficile Infection
NCT02797288 ·Status: UNKNOWN
-
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT06071312 ·Status: RECRUITING ·Phase: PHASE1/PHASE2